NCT02798965

Brief Summary

Lymphocytic thyroiditis is the most common autoimmune disease, usually affecting young women. Although the aetiology and pathogenesis remain obscure, the most widely accepted hypothesis is an interaction between a genetic predisposition and an environmental trigger factor such as viral infection. Parvovirus infections have been proposed as trigger factors for Hashimoto's thyroiditis and Graves' disease.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2010

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2010

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2014

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

June 9, 2016

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 14, 2016

Completed
Last Updated

November 19, 2025

Status Verified

November 1, 2025

Enrollment Period

3.4 years

First QC Date

June 9, 2016

Last Update Submit

November 17, 2025

Conditions

Graves Disease

Keywords

parvovirus genome

Outcome Measures

Primary Outcomes (1)

  • prevalence of circulating parvovirus genome

    Day 0

Study Arms (2)

Control

OTHER

patients with goiter or nodule

Biological: serodiagnosis

Graves' disease

EXPERIMENTAL

patients with Graves' disease

Biological: serodiagnosis

Interventions

serodiagnosisBIOLOGICAL
ControlGraves' disease

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Graves' disease :patients treated for Graves' disease, the diagnosis date less than 4 months
  • Control : patients cared for nodules or goiter

You may not qualify if:

  • Patients undergoing immunosuppressive therapy including corticosteroids

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Amiens

Amiens, 80054, France

Location

Related Publications (1)

  • https://www.em-consulte.com/article/753902/detection-de-levb19-parvovirus-b19-dans-les-thyroc

    RESULT

MeSH Terms

Conditions

Graves Disease

Interventions

Serologic Tests

Condition Hierarchy (Ancestors)

ExophthalmosOrbital DiseasesEye DiseasesGoiterThyroid DiseasesEndocrine System DiseasesHyperthyroidismAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

Immunologic TestsClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative TechniquesImmunologic Techniques

Study Officials

  • Rachel DESAILLOUD, MD, PhD

    CHU Amiens

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 9, 2016

First Posted

June 14, 2016

Study Start

December 1, 2010

Primary Completion

May 1, 2014

Study Completion

May 1, 2014

Last Updated

November 19, 2025

Record last verified: 2025-11

Locations

FR(1)